000			01838 a2200505 4500
005			20250517003514.0
264		0	_c20150930
008			201509s 0 0 eng d
022			_a1592-8721
024	7		_a10.3324/haematol.2014.117028 _2doi
040			_aNLM _beng _cNLM
100	1		_aGalanis, Allison
245	0	0	_aInhibition of c-Kit by tyrosine kinase inhibitors. _h[electronic resource]
260			_bHaematologica _cMar 2015
300			_ae77-9 p. _bdigital
500			_aPublication Type: Letter; Research Support, N.I.H., Extramural
650	0	4	_aAminopyridines _xtherapeutic use
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aBenzothiazoles _xtherapeutic use
650	0	4	_aBiomarkers _xanalysis
650	0	4	_aBone Marrow _xdrug effects
650	0	4	_aCell Line, Tumor
650	0	4	_aClinical Trials as Topic
650	0	4	_aDasatinib
650	0	4	_aGene Expression
650	0	4	_aHair _xdrug effects
650	0	4	_aHematopoietic Stem Cells _xdrug effects
650	0	4	_aHumans
650	0	4	_aIndazoles
650	0	4	_aLeukemia, Myeloid, Acute _xdrug therapy
650	0	4	_aNiacinamide _xanalogs & derivatives
650	0	4	_aPhenylurea Compounds _xtherapeutic use
650	0	4	_aPigmentation _xdrug effects
650	0	4	_aProtein Kinase Inhibitors _xtherapeutic use
650	0	4	_aProto-Oncogene Proteins c-kit _xantagonists & inhibitors
650	0	4	_aPyrimidines _xtherapeutic use
650	0	4	_aPyrroles _xtherapeutic use
650	0	4	_aSorafenib
650	0	4	_aSulfonamides _xtherapeutic use
650	0	4	_aThiazoles _xtherapeutic use
650	0	4	_afms-Like Tyrosine Kinase 3 _xantagonists & inhibitors
700	1		_aLevis, Mark
773	0		_tHaematologica _gvol. 100 _gno. 3 _gp. e77-9
856	4	0	_uhttps://doi.org/10.3324/haematol.2014.117028 _zAvailable from publisher's website
999			_c24381096 _d24381096